Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.

•Large cohort of patients with BRAF-mutant non–small-cell lung cancer (NSCLC).•No clear evidence that BRAF status influences progression-free survival (PFS) or overall survival in patients treated with chemotherapy.•Taxans were associated with poorest PFS in first-line in patients with BRAF mutant disease.•No significant difference in outcome between BRAF V600E or non-V600E compared with wild type controls.•Results re-enforce the strong place of targeted therapies in patients with BRAF-mutant NSCLC.